Peptides sold here

Type peptide into Google Trends and you'll find it has, sometime this spring, quietly overtaken pickleball, matcha, boba, and Labubu.¹ A looksmaxxing streamer who goes by Clavicular — Braden Peters, around two million followers across TikTok and Kick — rebuilt his body on camera using a weight-loss drug called retatrutide and a recovery compound called BPC-157, and turned "the stack" into the most-searched protocol of the year.² A bodega in Manhattan taped a glossy poster to its door, between the lottery sign and the cooler: PEPTIDES SOLD HERE. Someone threw a peptide speakeasy near Wall Street. Gwyneth Paltrow's podcast ran a segment; LeAnn Rimes told a magazine she does a daily shot.³

In April I wrote about how two people built a $400-million business selling compounded GLP-1s through an affiliate machine — the clean, telehealth, doctor-on-an-app version of the weight-loss boom.⁴ That was the gateway. This is what's behind the counter now: the same molecules' wilder cousins, sold with far fewer questions, to a generation that found them in a feed. It looks like a joke and a gold rush at the same time, and it is genuinely both. But underneath the meme is a real question worth taking seriously: how did a class of drugs that are, almost without exception, not approved for use in humans become a mainstream consumer category in about eighteen months?

The answer is three words, a generation of young men who want to be optimized, and a regulator that has been left reacting. Start with what's actually in the vial.

What's actually in the stack

The looksmaxxing shelf is broader than weight loss. There's retatrutide, Eli Lilly's still-experimental triple-agonist, which the internet has decided is the strongest fat-loss drug yet. There's BPC-157, a synthetic fragment marketed as a healing miracle for joints, tendons, and gut. There's GHK-Cu, a copper peptide for skin and hair; TB-500, MOTS-c, and KPV for recovery and longevity; PT-141 for libido; NAD+ for energy. The pitch is the optimization of the body, sold by the molecule.

Here's the part the feed leaves out. Of everything on that viral shelf, almost nothing is an approved human drug. The one clean exception — PT-141, approved by the FDA as Vyleesi — is for libido, and is the one compound nobody is looksmaxxing with. BPC-157, the emblem of the whole movement, is not approved as a drug anywhere on earth, is banned in sport at all times, and rests on a human evidence base that is close to non-existent: almost all of the published data traces to a single research group in Croatia.⁵ Retatrutide is still in trials — under federal law it legally cannot even be compounded.⁶ The shelf is mostly amber and red, with one lonely green.

The loophole is the product

So how is a website allowed to sell you an injectable, unapproved drug with no prescription? It isn't. It just says it's selling something else. Every vial carries the same label — "Research Use Only," often with a second line, "Not for human consumption." Those words are the entire architecture. They reclassify a drug as a laboratory reagent and the buyer as a scientist, and on that fiction the whole grey market stands.

The FDA is not fooled, and has said so in plain language: it has warned companies that "illegally sold unapproved drugs… falsely labeled 'for research purposes' or 'not for human consumption'" which were in fact "sold directly to consumers for human use with dosing instructions."⁷ The anti-doping agency USADA put it more drily about BPC-157: the sites call it a research chemical "not for human use," "and yet, the same websites have suggestions for how someone could use it."⁵ Everyone — seller, buyer, regulator — knows the label is a wink. It works anyway, because enforcement is slow and the demand is fast.

Underneath the wink is a supply chain built to stay invisible. Powder is sourced grey from China; storefronts are spun up as, in one reporter's phrase, "AI-slop" sites that redirect to a checkout for a commission; orders move over WhatsApp and get paid in stablecoin. A Fortune reporter, chasing the trend, bought a vial from someone named Louise for $109 in USDC.⁸ Demand from a feed, supply behind a label, settlement in crypto — that's the machine.

The two markets called "peptides"

If you go looking for the size of this thing, you'll hit a wall of confident numbers — "the peptide market will reach $294 billion by 2033," and so on.⁹ Ignore them. Not because they're wrong, but because they're answering a different question. That figure is the approved peptide-drug market: insulin, branded GLP-1s, oncology drugs — a real, enormous, mostly-Novo-and-Lilly business. The research firms can't even agree on it; their 2025–26 estimates run from about $50 billion to $141 billion depending on who's counting.⁹ None of it is the thing this essay is about.

The grey-market, research-use-only consumer boom has no reliable size at all — by design. The closest anyone has come is the crypto trail: a Chainalysis analysis reported by Fortune found peptide vendors took in about $32 million in crypto in the first quarter of 2026, up roughly 700% year over year, on pace for around $100 million for the year.⁸ Set that beside the headline market and you see the shape of it: the consumer boom everyone is arguing about is a rounding error on the boom nobody's arguing about — and it's the rounding error growing 700% a year.

Hot peptide summer

Where there's a hundred-million-dollar hole and a two-million-follower demand signal, there's a gold rush — and there is. The San Francisco Standard spent May cataloguing what it called "hot peptide summer": a wave of startups racing to put a brand on the grey market.¹⁰ There's Superpower Peptides, from Max Marchione, the 25-year-old founder who declared on X that "peptides will be the biggest consumer category of 2026."¹¹ There's NoHo Labs, which raised $16 million from Elad Gil and 8VC; The Protocole, a $6-million seed; a literal California Peptide Club whose first event drew a hundred-odd people; and Pink Pony Peptides, which kept selling after the FDA sent it a warning letter. Lawyers who do this work report five to ten calls a day from would-be founders.¹⁰ The VCs are split down the middle — Torch Capital bullish on the category, LongeVC waving it off because there's "no IP."

The most clarifying take came from a consumer VC, Aaron Miller of Will Ventures, who walked past one of those bodega posters and wrote down the actual thesis: the demand is real and rising, "but they have no clue where to buy them. And there's no household name brand that people trust for real ingredients and medical oversight. In the next few years that will change."¹² That is the whole opportunity in two sentences — and the whole problem. A category with mass demand and no trusted brand is a vacuum, and vacuums get filled. The question is whether they get filled by a real company or by the next "AI-slop" storefront.

Ban it, or bless it

Here's where the story stops being a meme and gets genuinely interesting, because the regulator is doing two opposite things at once.

On the GLP-1 side, the door has slammed. The FDA declared the semaglutide and tirzepatide shortages over (late 2024 into early 2025), which ended the legal basis for compounded copies by mid-2025; in April 2026 it proposed to permanently bar compounded semaglutide, tirzepatide, and liraglutide on an explicit finding of "no clinical need."¹⁴ Retatrutide — the looksmaxxers' favorite — is investigational and cannot be legally compounded at all.⁶ And on this side the harm is not hypothetical: by the end of May 2026 the FDA had logged 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide — numbers it says are undercounted — many from patients who drew five to twenty times the intended dose out of a vial.¹⁵ That part isn't a meme.

But for the recovery-and-longevity peptides — BPC-157, TB-500, MOTS-c, KPV — the FDA is doing close to the opposite of a crackdown. Its safety objection is honest but thin: not evidence of harm, but absence of evidence — no meaningful human safety data, possible impurities, hard-to-characterize ingredients.¹⁶ In April 2026 it quietly removed about a dozen of these peptides from its "significant safety risks" list.¹⁶ And on July 23–24, 2026 — next month — an FDA advisory committee is scheduled to vote on whether to add seven of them to the list of substances pharmacies are allowed to compound.¹⁷ That is not a ban. That is a possible on-ramp to legitimacy.

So the entire consumer scene is sitting on a coin flip it mostly doesn't know it's waiting on. If the committee says yes and the FDA follows, the bodega poster becomes a pharmacy shelf, and the gold rush has a legal product to sell. If it says no, the whole thing stays a research-chemical loophole, one enforcement wave from collapse. As of this writing, nobody knows which — and the people piling in are betting, whether they'd phrase it this way or not, that the regulator blinks.

$32M · +700%

Crypto paid to peptide vendors in Q1 2026 — a ~$100M/yr pace (Chainalysis)⁸

~2M

Followers of Clavicular, whose retatrutide transformation made "the stack" mainstream²

990 + 730

FDA adverse-event reports for compounded GLP-1s by May 2026 — the part that isn't a meme¹⁵

What's real, and what's a feed

The peptide summer is the cleanest example yet of a pattern the GLP-1 story started: demand and distribution now move faster than regulation, and a feed plus a loophole can manufacture a consumer category before the rules catch up. The creator economy supplies the want — one streamer's body, transformed on camera. The grey market supplies the molecule, behind a label everyone knows is a fiction. Crypto supplies the rails that keep it off the books. And the FDA supplies the only thing missing — a verdict, eventually, usually late. It's the same shape every new channel takes: the first money in comes from the businesses the polite channels won't quite take, and the rulebook gets written last.

Be honest about both halves. The demand is real: people genuinely want to optimize their bodies, and a few of these molecules may genuinely do something — we mostly don't know, because the studies don't exist. The companies are real, some funded by serious people. But a market built on unproven compounds, sold through a label that is a wink, priced in crypto to stay invisible, is not a stable category. It's a bet on a regulator's mood. The honest position isn't "peptides are a scam" or "peptides are the future." It's narrower and more interesting: this is real demand meeting unfinished science through an almost-legal supply chain, and the open question is whether it gets a legal body before it gets a body count.

Which is why the thing to watch isn't the next influencer or the next eight-figure raise. It's a committee meeting at the FDA's White Oak campus on July 23. The meme made the market; the vote decides whether the market gets to keep existing.